Gilead 3rd quarter profit rises, hepatitis C drug sales in line

October 27, 2015 8:21 PM

31 0

Oct 27 Gilead Sciences Inc on Tuesday said its quarterly profit rose 70 percent, but sales of its key hepatitis C drugs were largely in line with Wall Street estimates, and shares of the biotechnology company were little changed.

For the third quarter, Gilead posted net income of $4.6 billion, or $3.06 per share, compared with $2.7 billion, or $1.67 per share a year earlier. The company's shares, which rose 2 percent in regular trading, were up 0.05 percent at $111 after hours.

Also read: Chipmaker SK Hynix reports 64 percent jump in 1Q earnings

Read more

To category page